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Increased Matrix Synthesis Following Adenoviral Transfer
of a Transforming Growth Factor PI Gene
into Articular Chondrocytes
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Departnzents of *Orthopuedic Surgery and fMolecidnr Genetics and Biochemistry,
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, and $Department of
Orthopedic Surgery, Case WesfernReserve University, Clevelandj Ohio, U.S.A.

Summary: Monolayer cultures of lapine articular chondrocytes were transduced with first-generation adenoviral vectors carrying lacZ or transforming growth factor PI genes under the transcriptional control of the
human cytomegalovirus early promoter. High conccntrations of transforming growth factor PI were produced
by chondrocytes following transfer of the transforming growth factor P, gene but not the lacZ gene. Transduced chondrocytes responded to the elevated cndogenous production of transforming growth factor PI by
increasing their synthesis of proteoglycan, collagen, and noncollagenous proteins in a dose-dependent fashion. The increases in collagen synthesis were not accompanied by alterations in the collagen phenotype; typeI1 collagen remained the predominant collagen. Transforming growth factor PI could not, however, rescue
the collagen phenotype of cells that had undergone phenotypic modulation as a result of scrial passaging.
These data demonstrate that chondrocytes can be genetically manipulated to produce and respond lo the potentially therapeutic cytokine transforming growth factor PI. This technology has a number of experimental
and therapeutic applications, including those related to the study and treatment of arthritis and cartilage
repair.

Articular cartilage has a limited capacity to repair
damage sustained as a result of disease or injury (25).
Although there are a variety of surgical and pharmacological approaches to enhancing cartilage repair,
none is ideal (25). Improvements in understanding the
biology of articular chondrocytes have provided opportunities for improving the healing of articular cartilage by biological means. An attractive example of
this approach is to employ cytokines that increase matrix synthesis, decrease matrix breakdown, or d o both
(8,25,31).
Although such molecules hold much promise in this
regard, their clinical application is likely to be limited
by problems associated with the need for maintaining
high concentrations of these cytokines at sites of cartilage damage for sustained periods of time. Direct application of the substances themselves may not be
useful because of their short biological half-lives. For
example, it was recently reported that the half-life of
bone morphogenetic protein-2 (BMP-2) introduced
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into an expcrimental lesion in the articular cartilage of
rabbit knee joints is 4 days (14). One approach to solving this sort of problem involves the implantation of a
matrix that releases the factor at biologically relevant
concentrations. Gene transfer offers an alternative
approach (9).
Cytokines are proteins, and there are several potential advantages to delivering to cartilage the genes
encoding therapeutic cytokines rather than the cytokines theinselves (9). One advantage is that the reparative factors are synthesized locally in a sustained and
potentially regulatable fashion at the site of injury.
And, unlike recombinant factors produced by bacteria, those synthesized endogenously as a result of gene
transfer have undergone authentic post-translational
modification and may therefore have improved potencies. The feasibility of transferring genes to experimental lesions within articular cartilage has already
been demonstrated (5,20).
Transforming growth factor PI (TGF-PI) is a powerful modulator of cartilage metabolism, which can
promote matrix synthesis, inhibit matrix catabolism,
and alter chondrocyte proliferation rates in vitro and
in vivo (1 8,23,24,26,28,29,34). Moreover, TGF-P1can
counteract the suppressive effects of inflammatory
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mediators such as interleukin-1 (IL-1) on proteoglycan synthesis in cartilage (32,34). TGF-P1stimulates
replenishment of proteoglycans in depleted cartilage
in vivo (34), and osteoarthritic cartilage is more sensitive to TGF-/3 stimulation than is normal healthy
cartilage (21). Thus, TGF-P1may be well suited for use
in the repair of cartilaginous lesions resulting from arthritis or injury. Despite the beneficial effects of TGFP on cartilage, however, its effects on synovium are
deleterious. As a result, the direct introduction of
TGF-P,protein or genes (1,12,13,33,34)into joints can
be highly inflammatory and fibrotic, leading to cartilage degeneration and osteophyte formation. In view
of these properties, it is necessary to deliver TGF-P intracartilaginously under conditions in which the synovium is not exposed to this cytokine. The present
study therefore focuses on delivering the gene for
TGF-P1to articular chondrocytes with use of an adenoviral gene transfer system.

MATERIALS AND METHODS
Cell Isolation and Transduction
Articular cartilage was recovered from the knee and shoulder
joints of young adult (approximately 6 months old) New Zealand
White rabbits and diced into small pieces (15). Chondrocytes were

adenovirus or created with human TGF-P1protein purified from
platelets (R and D Systems, Minneapolis, MN, U.S.A.). Firstgeneration adenoviruses (AEI and AE3) containing a human
TGF-P1 gene or, as a control, the lacZ gene, under the transcriptional control of human cytomcgalovirus early promoter were
generated through Cre-lox recombination (I 6 ) and propagated in
293 cclls (American Type Culture Collection [ATCC], Rockville,
MD, U.S.A.). The virus containing the lacZ gene was used to assess the susceptibility of the cells to adenoviral transduction and
as a control for the effects of the TGF-P1 gene.
Transduction of cells with adenovirus containing the lacZ gene
(AdlacZ) or cDNA encoding human TGF'-Bl (AdTGF-PI) was
perfornicd in 300 p1 of Gey's balanced salt solution for 1 hour at
37°C at various multiplicities of infection. Following transduction,
thc remaining supernatant was removed and replaced with 1 ml
of serum-free Neuman-Tytell medium (GIBCOBRL. Grand Island, NY, 1J.S.A.) supplemented with antibiotics or Ham's F12
medium supplemented with 10% fetal bovinc serum and antihiotics (GrBco BRL). Cells serving as untransduced controls were
treated in the same manner as adenovirally transduced cells. To
assess the expression of P-galactosidase, the product of the lacZ
gene, cells were stained with 0.1% X-gal (5-bromo-4-chloro-3indolyl-B-D-galactose; Sigma Chemical, St. Louis, MO, U.S.A.) 48
hours after transduction by standard methods. The percentage of
the cells expressing lacZ was determined by visual inspection.
Nontransduced confluent cells were treated with purified TGF-PI
protein in scruni-less Neuman-Tytell medium. Following the transduction of cells or the addition of purified protein to serum-less
medium, the cells wcrc incubated for 24 hours before the addition
of radionuclides uscd to determine the synthesis of matrix compo-
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FIG. 1. Production of transforming growth factor P1 (TGF-Pl) by chondrocytes. Supernatant from control cells and cells transduced with
increasing amounts of adenovirus containing cDNA encoding human TGF-PI (AdTGF-B,) were recovered. Latent TGF-PI was activated
by heating. Active TGF-PIwas assayed by enzyme-linked immunosorbent assay (ELISA) and bioassay. In all assays, unlransduced control
cells produced negligible amounts of TGF-P1. Supernatants from cells transduccd with adenovirus containing the lacZ gene (AdlacZ) also
produced negligible amounts of TGF-P1(data not shown). MOT = multiplicity of infection.
released by the sequential digestion of the cartilage fragments
with trypsin (2% wtivol; 30 minutes) and collagenase (2% wtivol;
3 hours). The chondrocytes were seeded into monolayer culture
at a density of lo5 cellsicm' on 24-well plates with use of Ham's
F12 nutrient medium supplemented with 10% fetal bovine serum
and 1 % penicillin-streptomycin in a humidified atmosphere of 5%"
C 0 2 at 37°C. For most experiments, cells wcre used without passaging. In those experiments in which thc cffects of passaging
were evaluated, confluent monolayers were trypsinized (0.2%
trypsin; 30 minutes), washed, and rcseeded into nutrient medium
at a 1:2 split ratio. This process was rcpcated to generate thirdpassage cells.
Two treatment groups comprised cells either transduced with
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nents. Expcriments were run in duplicate (i.e., n = 2 for each experiment). Each experiment was run at least twice (i.e,, total n =
4) or three times (i.e., total n = 6 ) .

Determinationof TGF-PI Concentration
Latent TGF-P, was converted to activc TGF-B1by healing the
sample at 80°C for 15 minutes. TGF-P, concentrations in conditioned media were determined with a commercially available
enzyme-linked immunosorbent assay (ELTSA) kit and protocol
(R and D Systems) and by the mink lung cell bioassay (19).
The ELISA protocol is a sandwich assay in which samples are
added to 96-well plates coated with the type-IT TGF-P soluble receptor. This captures any TGF-P, in the sample, which is detected
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FIG. 2. Proteoglycan synthesis in response to transforming growth Cactor PI (TGF-PI) (A) exogenously applied protein and (B) endogenously synthesized by transduced cells. A: Exogcnous TGF-PI. Confluent chondrocytes were treated with different cmccntrations
of purified, active TGF-0, for a total of 48 hours prior to determination of protcoglycan synthesis. The growth factor was replenished in
the serum-free media after 24 hours. A dose-dependent increase in proteoglycan synthesis was obtained with increasing conccntrations
of TGF-P1. The individual data points are averages from triplicate experiments (n = 6) with results reported as mean ? SD. B Endogenous TGF-0,. Confluent chondrocytcs were transduced with adenovirus containing the lacZ gene or cDNA encoding human TGF-0,
(AdlacZ or AdTGF-PI) in the concentrations indicated and subsequently maintained for 48 hours in serum-free media or media containing 10% fetal calf scrum. Mean -t SD of triplicate experiments (n = 6) are shown. GAG = glycosaminoglycan, and MOI = multiplicity
of infection.
by an anti-TGF-PI antibody covalently linked to peroxidasc. A
colorimetric assay is used to measure the activity of the bound
peroxidase, which is converted to TGF-(3, concentration by a standard line. The assay fails to detect latent TGF-PI because the
epitopes recognized by the enzyme-linked antibody are hidden by
the latency-associated protein.
For the bioassay, bovine serum albumin (1ngiml) and 1 pgiml
of each of the proteinase inhibitors aprotinin, leupeptin, and
pepstatin were added to conditioned nicdia. Mink lung epithelial
cells (American Type Culture Collection [ATCC]) were seeded
into 24-well plates with minimal Eagle medium supplemented
with 10% fetal bovine serum, serum antibiotics, and glutamine.
Six hours later, the medium was changed to one with only 0.5%
fetal bovine scrum and the culture continued for 18 hours. At
this time, the chondrocyte-conditioned media or purified TGFPI standards were added and incubation continued for an additional 6 hours. The cultures wcrc then pulse-labeled with
[3H]thymidinelor 2 hours, and the incorporation of radioactivity
into material precipitated by trichloroacetic acid was measured
by liquid scintillation.

Proteoglycan and Collagen Synthesis
To determinc the effect of TGF-P1 on matrix production, the
synthesis of protcoglycan by adenovirally transduced chondro-

cytes and chondrocytes treated with exogenously added TGFPI was measured. The synthesis of proteoglycans was measured
as the incorporation of ”SO:into glycosaminoglycans (30).
Na2[”S]O:- (40 pCi[1,480 X lo3 Bqliml) was added to the cultures, and incubation continued for an additional 8 hours. The
cells and media were then extracted with 4 M guanidinium
hydrochloride. and the radioactivity incorporatcd into proteoglycans was separated from unincorporated precursor by
size-exclusion chromatography on PD-10 columns (Pharmacia,
Piscataway. NJ, U.S.A.).
[‘Hlproline was used to label newly synthesized collagen and
noncollagenous proteins (7). Cells were incubated for 24 hours
with 5 pCi(l85 X lo3 Bq)/ml [3H]proline (specific activity 55
Ci[2,035 X lo9Bq]/mmol). At the end of the incubation period,
newly synthesized proteins were recovered from the medium and
cell layer and digcsted with highly purified collagenase ABC form
IT1 (Advanced Biofacturcs, Lynbrook, NY, U.S.A.) producing a
soluble fraction reprcscnting collagen production. Collagenaseresistant matcrial was digested with papain to release radioactivity incorporated into noncollagenous proteins. Because TGF-0,
has been reported to increase the production of type-I collagen
in other cell types (18,27), collagen phenotyping was performed
to analyze the types of collagens produced in basal and TGF-PIstimulated states. Collagen phenotyping was performed by a pre-
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FIG. 3. Synthesis of collagen and noncollagenous proteins by chondrocytes in response to transforming growth factor PI (TGF-PI ) (A) exogenously added protein and (&) endogenously synthesized by transdueed cells. A Exogenous TGF-PI. Confluent cells were treated with
different concentrations of purified, active TGF-P,for a total of 48 hours prior to determination of proteoglycan synthesis. The growth factor was replenished in the scrum-free media after 24 hours. Data points are means of triplicate experiments (n = 6) i SD. B: Endogenous
TGF-pI. Confluent chondrocytes were transduced with adenovirus containing the lacZ gene or eDNA encoding human TGF-PI (AdlacZ
or AdTGF-PI) at the multiplicities of infection (MOI) indicated and subsequently grown for 48 hours prior to determination of collagen
and noncollagenous protein synthesis. Means of duplicate experiments (n = 4) are shown.

viously described method ( 7 ) following the separation of samples
by sodium dodccyl sulfate-polyacrylaniide gel electrophoresis
(SDS-PAGE) on 7.5% gels. Briefly, extracts were treated with
pepsin (100 pgiml) in 0.5 M acetic acid and digested for 4 hours.
The digests were dialyzed against 0.05 M NH,HCO1, dried, and
analyzed by SDS-PAGE. Gels were treated with EN’HANCE
(DuPont-NEN, Boston, MA, U.S.A.) prior to autoradiography.
Densitometric analysis of autoradiograms was performed to determine the relative abundance of type-I and type-I1 collagen with
the BIO-RAD GS-670 imaging densitometer (Bio-Rad Laboratories, Richmond, CA, U.S.A.). The positions of al(1) and ul(I1)
chain migration on the gels were determined with purified type-I
and type-I1 collagen run as standards on the same gels.

Matrix Metalloproteinase (MMP) Assays
Conditioned media were assayed for collagenase, gelatinase,
and stromelysin with use of radiolabeled substrates (3). Casein
(Sigma Chemical) and type-I bovine collagen (Vitrogen; Collagen
Corporation, Palo Alto. CA, U.S.A.) were radiolabeled with tritiatcd acetic anhydride. Aliquots of [3H]collagen were heated to
60°C for 30 minutes to form gelatin. Assays were run in reaction
buffer containing SO mM Tris, 0.2 M NaCI. and 5 mM CaCl,, p H
7.4. Assay mixes contained 50 p1 radioactive substrate, 50 p1 con-
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ditioned media, and 100 pl reaction buffer. Aminophenylmercuric
acetate (1 mM) was added to activate latent enzyme. Reactions
were allowed to proceed for 4 hours at 37°C for caseinase (predominantly stromelysin) and gelatinase and 25°C for collagenase
activity. The reactions werc terminated by the addition of 250 pl
10% trichloroaeetic acid, and thc radioactivities of the trichloroacetic acid soluble material were measured by liquid scintillation.

RESULTS
With use of a multiplicity of infection of 50, essentially all chondrocytes were positive for lacZ (data not
shown). No toxicity was observed at any multiplicity
of infection. Naive cells did not secrete detectable
amounts of MMPs, and transduction of cells with adenovirus did not induce collagenase, gelatinase, or
stromelysin activities (data not shown).
Cells infected with AdTGF-P1 produced elevated
amounts of TGF-P1protein as determined by ELISA
(Fig. 1). Estimates of TGF-PI concentration by the
mink lung cell bioassay provided values in close
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FIG. 4. Quantitativc and qualitative effects of transduction with adenovirus containing cDNA encoding human transforming growth factor
PI (AdTGF-PI) on the collagen produced by chondrocytes. A Coomassie blue-stained gel reveals the presence of a major collagen band
migrating in the al(I)/al(II) position. Autoradiography (inset) shows that in addition to type-I1 collagen chains, the newly synthesized collagen is composed of bands that co-migrate with al(V)la,(XI) and a&) chains. B: Densitometric scanning of protein bands on autoradiograms confirms an increase in collagen synthesis in response to TGF-PI produced by transduced chondrocytes. Values under each
individual lane represent the amount of collagen synthesized, based on a control value o f 100% (lane 1). C: Equal amounts of radioactive
collagen (50,000 cpm/well) were loaded and separated on a 7.5”/0sodium dodecyl sulfate-polyacrylamide electrophoresis gel. Equal band
intensities were obtained regardless of treatment. Densitometric scanning of the protein bands confirmed that 80% of the newly synthesized collagen was type 11. The percentage of type-I1 collagen is given under each individual lane. In each panel, lanes 2-6 represent cells
with increasing multiplicities of infection (MOI) of AdTGF-PI

agreement with the ELISA data. Most of the TGF-P1
in the conditioned media was latent (Fig. 1).
The addition of TGF-PIto cells maintained under
serum-free conditions produced a dose-dependent,
saturable response with a 225 % increase in proteoglycan synthesis obtained with 2.5 ng/ml TGF-P1 (Fig. 2).
Cells transduccd with AdTGF-D, also synthesized

proteoglycans at elevated rates, with 1 multiplicity of
infection increasing production to 175% of control
and 5 multiplicities of infection increasing production
to 275 % of control (Fig. 2B). These levels of stimulation are approximately equal to those obtained with
the addition of purified protein at the concentrations
achieved by gene transfer. The use of an adenoviral
J Orzhop Res, Vol. 18, No. 4, 2000
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control (AdlacZ) demonstrated that the effect was
due to the presence of TGF-P1and not to the adenoviral transfection protocol. The stimulatory effect of the
TGF-P1transgene was potentiated in the presence of
10% fetal bovine serum with the lowest concentration
of virus, AdTGF-8, at 1 multiplicity of infection, increasing production 3-fold (Fig. 2B, serum).
TGF-P1also increased the synthesis of collagen and
noncollagenous proteins in a dose-dependent, saturable fashion (Fig. 3A). Maximal increases in protein
synthesis were obtained with 1.25 to 2.5 ng/ml TGFP1, elevating the synthesis of collagen and noncollagenous protein to 362 and 353% of control, respectively.
Adenovirally induced production of TGF-P1 resulted
in a dose-dependent increase in collagen (Fig. 3B) and
noncollagenous protein synthesis. Thus, TGF-P1produced endogenously by chondrocytes as a result of
gene transfer increased the synthesis of both proteoglycan and collagen to approximately the same degree as exogenously applied TGF-P1.
Separation of collagen molecules on the basis of
molecular size was performed with SDS-PAGE (Fig.
4). The type-I1 collagen standard co-migrated with the
major collagen band produced in untreated and infected primary chondrocytes. A band corresponding
to the a2(I) chain was barely visible on these Coomassie blue-stained gels, demonstrating that type-I1
collagen is the predominant collagen produced in
these cells. The darker bands at the bottom of the gel
in Fig. 4A are due to the addition of pepsin. Autoradiography was performed to establish the effect of
TGF-P1treatment on collagen production. Total collagen synthesis was assessed, and an autoradiogram is
shown (Fig. 4B). The increase in the density of bands
generated after treatment of cells with AdTGF-PI
confirms that adenovirally induced production of
TGF-S, is capable of increasing collagen synthesis.
The greater sensitivity of autoradiography compared
with staining with Coomassie blue permitted detection of a small amount of u2(I) collagen chains. Collagen phenotyping was performed on gels where
equal counts were loaded (Fig. 4C). Band intensities
for type-I and type-I1 collagens did not vary among
treatment groups; densitometric analysis revealed an
average of 80% type-I1 collagen produced in all
groups on the basis of the assumption that the ratio of
a1(T):a2(1) chains is 2:l. This is the same percentage
of type-I1 collagen as made by untreated, unpassaged
chondrocytes (data not shown).
In view of the ability of TGF-P1to increase the synthesis of collagen by chondrocytes while maintaining
the predominantly type-TI collagen phenotype, we undertook a series of experiments to determine whether
TGF-PI could rescue the collagen phenotype of cells
that had been serially passaged. In these experiments,
cells were exposed to TGF-PI from 48 hours to 5 days.
J Orthop Res, Vol. 18, No. 4, 2000

The representation of type-TI collagen decreased from
approximately 80% in unpassaged cells to 53% in
cells at the second passage and 28% in cells at passage
three (data not shown). The addition of as much as 2
ngiml TGF-P1 increased total collagen synthesis but
failed to restore the representation of type-TI collagen
(data not shown). The TGF-P3isoform was also unable to elevate the proportion of type-I1 collagen synthesized by these cells (data not shown). Because
TGF-P protein had no effect on the collagen phenotype of the passaged cells, experiments with transduced cells were not attempted.

DISCUSSION
These data confirm that articular chondrocytes are
susceptible to transduction with adenoviral vectors,
efficiently express a TGF-P1 transgene delivered by
such vectors, and respond to the secreted product by
increasing matrix synthesis. The increment in matrix
synthesis resulting from transgene expression was approximately equal to that achieved by adding a similar
amount of purified human TGF-PI. Importantly, collagen synthesized in the presence of TGF-P1remained
predominantly type 11; it is well known that excessive
production of type-I collagen leads to defective repair
tissue that ultimately fails. Although TGF-P1was able
to maintain the collagen phenotype of unpassaged
cells, it could not rescue that of passaged cells, which
produce predominantly type-I collagen. This observation is of relevance to the use of autologous chondrocyte transplants in repairing cartilaginous defects,
where the cells undergo multiple cell divisions before
reimplantation (6).
While this work was in progress, Arai et a]. (2) reported complementary studies in which adenoviral
transfer of a TGF-PI gene to a human chondrocytic
cell line in vitro increased the abundance of aggrecan
core protein mRNA while decreasing the abundance
of stromelysin mRNA. They did not study collagen
gene expression. As well as promoting the repair of
cartilaginous lesions produced by trauma, the TGF-P1
gene may be particularly useful in osteoarthritis,
where the chondrocytes are hyper-responsive to TGFPI (21). This is the opposite of their response to
insulin-like growth factor-1 (IGF-l), which is depressed in osteoarthritis (22).
The intraarticular activity of TGF-P needs to be
carefully controlled. Intraarticular injection of TGF-P
protein, or delivery of AdTGF-P to the synovium,
leads to inflammation, osteophyte formation, fibrosis,
and cartilage erosions (1,12,33,34). Tn contrast. transfer of the TGF-PI gene to a limited number of cells
within a cartilaginous lesion should allow for the local
production of TGF-P1,the concentration of which will
be high within the lesion but extremely low elsewhere.
In this way, cartilage repair could be accelerated
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without provoking additional adverse intraarticular
disturbances.
Clearly, this approach can be used with genes other
than TGF-PI. A variety of interesting growth factors,
including certain members of the BMPs, fibroblast
growth factor, IGF, platelet-derived growth factor,
and hedgehog families of proteins, await evaluation
(8). In addition, IL-1 suppresses cartilage repair by
both inhibiting the synthesis and accelerating the
breakdown of matrix. Baragi et al. (4) have shown
that transfer of the IL-1 receptor antagonist (IL-1Ra)
gene to chondrocytes protects cartilage from the catabolic effects of IL-1 in vitro. Delivery of the IL-1Ra
gene to the synovial lining of joints ameliorates experimental models of rheumatoid arthritis and osteoarthritis (11) and is in a phase-I clinical trial for human
rheumatoid arthritis (10).
The data presented in this paper encourage the further development of gene-based methods for preserving and repairing articular cartilage.
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